A study evaluating safety of Tocilizumab, IL-1 inhibitors Anakinra & Canakinumab and Etanercept in patients with Juvenile Idiopathic Arthritis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Tocilizumab (Primary)
Indications Juvenile rheumatoid arthritis
Focus Adverse reactions

15 Jun 2019 Results (n=48) assessing safety of canakinumab in pediatric patients, presented at the 20th Annual Congress of the European League Against Rheumatism.
16 Jun 2018 Results of a cohort of patients who started first-line anakinara (n=47) presented at the 19th Annual Congress of the European League Against Rheumatism.
17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com